The data on retatrutide—which is not yet approved by the U.S. Food and Drug Administration (FDA)—raise the question of what role each of the growing number of drugs in this category will have in managing obesity, and whether some may become redundant. The medications come in injectable form (Wegovy and Zepbound) as well as in pills (Wegovy pill and Foundayo). Side effects are an important factor in how people chose a weight-loss medication, and while all of the drugs in this category come with GI-related side effects including nausea, vomiting, and diarrhea, some people experience more severe symptoms than others on certain drugs. In the current study, about 11% of people on the highest dose of retratutide stopped taking the drug because of the side effects, which is about the same rate as those who dropped out of the tirzepatide studies that Lilly conducted. Real-world studies show the drop-out rate may be slightly higher, at about 15%.
Read the full article here
